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Background: Lobectomy with preservation of the contralateral lobe has already become
the most preferred surgical method for patients with low-risk thyroid cancer. The
incidence of and risk factors for the development of hypothyroidism after lobectomy for
thyroid cancer remains unclear. The previous practice of levothyroxine supplementation
post-thyroidectomy, to bring about thyroid stimulating hormone (TSH) suppression,
had some serious side effects. This study aimed to evaluate the incidence of
hypothyroidism and to identify the factors associated with hypothyroidism requiring
thyroid hormone replacement.
Methods: We retrospectively reviewed the charts of 256 consecutive patients with
differentiated thyroid cancer treated with lobectomy at the Gangnam Severance Hospital
between April and December 2014 who were followed-up for more than 5 years. Patients
were evaluated using a thyroid function test at the time of outpatient visit every 6 months
for the 1st year, with an annual follow-up thereafter.
Results: After 5 years, 66.0% (169) of the patients needed levothyroxine
supplementation to maintain euthyroid status. The incidence of hypothyroidism requiring
levothyroxine supplementation increased until 3 years but showed no significant change
in the 4 and 5th year. Recurrence showed no difference between the group with and
without levothyroxine supplementation. The presence of thyroiditis and preoperative
TSH levels were correlated with postoperative levothyroxine supplementation to maintain
euthyroid status, in univariate and multivariate analyses.
Conclusion: High preoperative TSH levels and/or thyroiditis indicate a significantly
increased likelihood of developing hypothyroidism requiring thyroid hormone
supplementation after a thyroid lobectomy. Patients with an increased risk of
postoperative hypothyroidism must be aware of their risk factors and should undergo
more intensive follow-ups.
Keywords: thyroid stimulating hormone suppression, hypothyroidism, low-risk differentiated thyroid cancer,
levothyroxine supplementation, thyroid lobectomy
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INTRODUCTION
With the improvement in early diagnosis, the proportion of
patients with low-risk differentiated thyroid cancer (DTC) is
also increasing. Lobectomy with preservation of the contralateral
lobe has already become the most preferred surgical method for
patients with low-risk thyroid cancer (1).
The incidence of and risk factors for the development of
hypothyroidism after lobectomy remain unclear. Several studies
have demonstrated an incidence of post-thyroidectomy
hypothyroidism ranging from 9 to 43% depending on
the duration of follow-up evaluation and the definition of
hypothyroidism among patients who undergo lobectomy (2–4).
Thyroiditis, preoperative thyroid stimulating hormone (TSH)
levels, and positivity for thyroid antibodies have been reported to
be the most important risk factors for early and late postoperative
hypothyroidism (2, 5, 6).
The American Thyroid Association guidelines recommend
TSH levels to be in the mid to lower reference range (0.5–2
mU/L) for low-risk patients who have undergone lobectomy,
with continued surveillance for recurrence (1). The purpose of
levothyroxine therapy is not only to replace the endogenous
thyroid hormone to treat hypothyroidism but also to prevent
the relapse or progression of thyroid cancer; furthermore, it
plays a central role in papillary thyroid carcinoma (PTC)
management after thyroidectomy (5, 7). TSH suppression,
resulting in serum TSH levels below the lower limit of the
reference range, was proposed as a therapeutic intervention
in thyroid cancer, on the assumption that subnormal serum
levels of TSH would slow the growth and spread of thyroid
cancer cells (8).While TSH suppression improves disease specific
survival in high-risk patients, its benefits in low-risk patients is
controversial (5, 7).
TSH suppression, brought about by the long-term
administration of supraphysiological doses of levothyroxine,
could cause some serious side effects including symptoms and
signs of hyperthyroidism and impaired psychological, social, and
physical quality of life (9, 10). Increased risks of osteoporosis
and fractures, particularly in postmenopausal women, have been
reported (11). Moreover, adverse effects on the heart including
increased cardiovascular morbidity and mortality are known to
be associated with TSH suppression (9, 10, 12).
Defining the risks of hypothyroidism is crucial for developing
better preoperative counseling and management strategies and
follow-up strategies for patients undergoing this lobectomy.
Until now, not much is known about which patients should be
carefully followed-up and how the interval of follow-up should
be modified.
This study was designed to evaluate the incidence and timing
of development of hypothyroidism after lobectomy and to
analyze the relationship of post-thyroidectomy hypothyroidism
with preoperative parameters and histopathological findings.
Abbreviations: DFS, Disease-free survival; DTC, Differentiated thyroid cancer;
PTC, Papillary thyroid carcinoma; SD, Standard deviation; TSH, Thyroid
stimulating hormone; CI, Confidence interval.
MATERIALS AND METHODS
Patients
Among the patients who visited the Thyroid Cancer Clinic
at Gangnam Severance Hospital, Yonsei University, 256
consecutive patients who underwent lobectomy for low-risk PTC
from April 2014 to December 2014 were enrolled. Patients who
had an aggressive variant of papillary thyroid cancer or poorly
differentiated thyroid cancer were not included. Patients with
preoperative hypothyroidism, defined as patients with known
diagnosed hypothyroidism, patients receiving preoperative
thyroid hormone treatment for any reason, or patients with
baseline TSH levels above the upper limit of the normal range
at our institution (0.86–4.69 mcIU/mL) were excluded from
the study.
The study was carried out in accordance with the principles
laid out in the World Medical Association’s Declaration
of Helsinki, Good Clinical Practice, and associated Korean
regulations. This study was approved by the Institutional Review
Boards of Gangnam Severance Hospital. Since patients’ identities
remained undisclosed as data were obtained retrospectively and
since informed consent is notmandatory for retrospective studies
in Korea, the institutional review board waived the need for
informed consent.
A lobectomy was defined as the resection of either the right
or left thyroid lobe with preservation of the isthmus and the
contralateral thyroid lobe.
All patients were followed-up postoperatively for at least 5
years from 2014 to 2019. Outpatient follow-up was carried out
according to a basic routine protocol: (1) outpatient visits every
6 months for the 1st year, with an annual follow-up thereafter,
(2) a thyroid function test at every visit, and (3) an annual
sonography follow-up.
Definition of Hypothyroidism
Postoperative hypothyroidism was defined as a serum TSH
level greater than the normal range at our institution (0.86–
4.69 mcIU/mL). Thyroiditis was defined as either the presence
TABLE 1 | Baseline characteristics of the patients who underwent lobectomy.
Total patients (n = 256)
Age (years, mean ± SD) 43.79 ±10.92
Male 52 (20.3%)
Female 204 (79.7%)
Preoperative TSH (mcIU/mL, mean ± SD) 1.79 ± 0.94
Tumor size (cm, mean ± SD) 0.72 ± 0.46
Thyroiditis Yes 87 (34.0%)
No 169 (66.0%)
N stage N0 187 (73.0%)
N1a 69 (27.0%)
Recurrence 3 (1.2%)
Mean f/u (days, mean ± SD) 1998.7 ± 92.5
TSH, thyroid stimulating hormone; SD, standard deviation; f/u, follow-up.
Frontiers in Endocrinology | www.frontiersin.org 2 July 2020 | Volume 11 | Article 520
Kim et al. TSH Suppression in Lobectomy Patients
FIGURE 1 | Incidence of hypothyroidism and levothyroxine supplementation. A significant increase in incidence was observed until 3 years (p < 0.001), whereas after
3 years, there was no significant increase (*p > 0.05, analyzed by the McNemar’s test).
of positive antibodies preoperatively (anti-thyroid peroxidase
antibody or anti-thyroglobulin antibody) or if thyroiditis was
diagnosed in a pathologic report.
Levothyroxine supplementation was administered to patients
with TSH levels higher than the upper limit of the normal range
at our institution.
Statistical Analysis
Descriptive statistics were used to describe the basic
characteristics of the two groups. Continuous variables,
expressed as mean ± standard deviation (SD), were compared
using the Student’s t-test. Pearson’s chi-square test, Fisher’s
exact test, and McNemar’s test were used for categorical
variables, expressed as numbers and percentages. Univariate
and multivariate analyses were performed by logistic regression
analyses. All statistical analyses were performed using SPSS
version 23.0 for Windows (SPSS Inc., Chicago, IL, USA). In
all statistical analyses, a two-tailed p < 0.005 was considered
statistically significant.
RESULTS
The clinicopathological characteristics of the patients included
in the study are presented in Table 1. Of the 256 included
patients, 169 (66.0%) needed levothyroxine supplementation
during follow-up. In three patients (1.2%), recurrence was
observed. Investigation of the recurrence site revealed that
recurrence occurred in different sites in the three patients:
contralateral lobe recurrence, early lung metastasis, and lateral
lymph node metastasis.







Age (years, mean ± SD) 43.31 ± 10.21 44.04 ± 11.28 0.032
Sex (Female) 70 (80.5%) 134 (79.3%) 0.826
Preoperative TSH (mcIU/mL,
mean ± SD)
1.40 ± 0.59 1.99 ± 1.02 <0.001
Tumor size (cm, mean ± SD) 0.77 ± 0.47 0.69 ± 0.44 0.452
Thyroiditis 22 (25.3%) 65 (38.5%) 0.035
Lymph node metastasis (N1a) 24 (27.6%) 45 (26.6%) 0.870
Recurrence 0 (0%) 3 (1.2%) 0.211
TSH, thyroid stimulating hormone; SD, standard deviation.
Bold values indicates statistically significant different (p < 0.05).
The patients were followed-up for a duration of 5 years.
After lobectomy, 19.5% of patients were diagnosed with
hypothyroidism immediately postoperatively, and levothyroxine
supplementation was started. The incidence of hypothyroidism
(with the need of levothyroxine supplementation) increased
significantly during the first 3 years of follow-up (p < 0.001).
After 3 years, there was no significant increase in the incidence
of levothyroxine supplementation (Figure 1).
There were no significant differences in sex, tumor size,
lymph node metastasis, and recurrence between the groups
with and without levothyroxine supplementation. However, age,
preoperative TSH levels, and the presence of thyroiditis were
significantly different between the two groups (Table 2).
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TABLE 3 | Univariate and multivariate analyses for clinical factors associated with levothyroxine supplementation.
No levothyroxine (n = 87) Levothyroxine (n = 169) Univariate Multivariate
OR (95% CI) p-value OR (95% CI) p-value
Age
(years, mean ± SD)
43.31 ± 10.21 44.04 ± 11.28 1.006 (0.982–1.030) 0.614 1.002 (0.976–1.028) 0.889
Sex
(Female)
70 (80.5%) 134 (79.3%) 1.076 (0.563–2.055) 0.826 1.138 (0.570–2.271) 0.714
Preoperative TSH
(mcIU/mL, mean ± SD)
1.40 ± 0.59 1.99 ± 1.02 2.229 (1581–3.142) <0.001 2.271 (1.598–3.227) <0.001
Thyroiditis 22 (25.3%) 65 (38.5%) 1.847 (1.040–3.279) 0.036 2.021 (1.092–3.738) 0.025
TSH, thyroid stimulating hormone; SD, standard deviation; OR, odds ratio; CI, confidence interval.
In the univariate analysis, there was no correlation between
age, sex, and the development of postoperative hypothyroidism,
and the need of levothyroxine supplementation. Preoperative
TSH levels and the presence of thyroiditis had a significant
impact on the incidence of hypothyroidism and levothyroxine
supplementation. This was also shown in the multivariate
analysis (Table 3).
DISCUSSION
Our study showed that 66.0% of the patients who underwent
lobectomy for PTC developed hypothyroidism and needed
levothyroxine supplementation. An increase in the number of
hypothyroid patients was observed during the first 3 years of
follow-up, but after 3 years, there was no significant increase.
The factors associated with hypothyroidism were preoperative
TSH levels and thyroiditis. There was no difference in recurrence
according to the use of levothyroxine supplementation. Although
the patients in this study did not undergo TSH suppression and
their TSH levels were maintained in the normal range considered
in our hospital, there were only three recurrent cases.
In another study, the authors suggested that they may be able
to predict the possibility of developing post-hemithyroidectomy
hypothyroidism, especially in the presence of preoperative
positivity for microsomal and thyroglobulin antibodies and high-
grade lymphocytic infiltration of the resected gland (13). Since we
defined “thyroiditis” as the presence of high preoperative levels of
antibodies or lymphocytic infiltration in the pathologic report,
our study showed the same results. Stoll et al. (14) reported
that higher mean preoperative TSH levels, lower preoperative
T4 levels, and the presence of Hashimoto’s thyroiditis were
significant risk factors for hypothyroidism. Specifically, patients
with preoperative TSH levels >1.5 uIU/mL had a higher
proportion of hypothyroidism. Furthermore, female sex could
also be a potential risk factor for hypothyroidism after thyroid
lobectomy, although this factor only showed a trend toward
statistical significance. However, the above studies only included
patients with benign pathology, while patients with malignancy
were excluded.
The increase in the number of patients who needed
levothyroxine supplementation was significant during the first
3 years, whereas there was no significant increase after 3 years.
Therefore, we suggest that after lobectomy, patients should be
regularly followed-up within short time intervals of 6–12 months
for the first 3 years; after 3 years, the follow-up duration can
be widened. One study reported that the majority of patients
with hypothyroidism were detected during the first 6 months
post-operation, and the authors suggested regular follow-ups for
serum TSH testing for at least 12 months (13).
Studies have reported that about 14.3–42.6% of patients
require thyroid hormone replacement after lobectomy. However,
these studies included patients with benign disease and used
higher TSH levels to define hypothyroidism (2, 13, 14).
In our study, there was no TSH suppression, and TSH levels
were maintained in the normal range (0.86–4.69 mcIU/mL).
However, there was no difference in recurrence depending
on the incidence of hypothyroidism, and only three patients
showed recurrences in this population during the 5 years of
follow-up, suggesting that for low-risk DTC patients, there
is no need for TSH suppression, and it is sufficient to
maintain their TSH levels within the normal range. The
findings of the study by Lee et al. support our findings in
that considering the excellent prognosis of low-risk DTC and
limitations of the effects of TSH suppression therapy, TSH
suppression treatment is not necessary for patients who undergo
lobectomy for low-risk DTC (15). Another study reported
that serum TSH levels did not affect short-term recurrence in
patients with low-risk DTC after thyroid lobectomy. During
a 5-years follow-up, 1.4% of patients experienced recurrence.
The mean TSH values did not affect recurrence-free survival.
However, the mean TSH levels of patients in their study were
within the recommended low-normal range (0.5–1.9 mIU/L)
(16). Furthermore, a randomized controlled trial with low-
risk PTC patients showed that disease-free survival (DFS) in
patients without TSH suppression was not inferior by more
than 10% to the DFS in patients with TSH suppression. The
authors suggested that thyroid-conserving surgery without TSH
suppression should be considered for patients with low-risk PTC
to avoid the potential adverse effects of TSH suppression (17).
However, the follow-up time in our study was only 5 years and
required a more prolonged time of observation to follow-up
for recurrence.
Research has been conducted not only on the effect
of TSH suppression on cancer recurrence but also on its
role in the prevention of nodular recurrence of benign
disease. It has been reported that prophylactic levothyroxine
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treatment after lobectomy significantly decreased the
recurrence rate of nodular goiter in the contralateral thyroid
lobe as well as the need for completion thyroidectomy,
mostly among patients with iodine deficiency (18).
Levothyroxine therapy may prevent the recurrence of
nodular disease; furthermore, levothyroxine therapy at a
substitutive dosage may be sufficient compared to TSH
suppression (19).
In conclusion, interpretation of these results and
related literature has several practical implications in
clinical settings. High preoperative TSH levels and/or
thyroiditis should alert the clinician to a significantly
increased likelihood of hypothyroidism development and
the requirement of thyroid hormone supplementation
after thyroid lobectomy. Patients with an increased risk
of postoperative hypothyroidism must be aware of their
risk factors and should undergo more intensive follow-ups.
However, two-thirds of patients who undergo lobectomy
need levothyroxine supplementation; thus, from a practical
standpoint, all patients who undergo lobectomy should be
counseled regarding the potential need for lifelong thyroid
hormone therapy.
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